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IR and EI-MSAbstract Heterocyclic compounds are the most attractive class for researchers due to their biolog-
ical activities. In the undertaken research, a number of N-(5-chloro-2-methoxyphenyl)-4-(5-substi-
tuted-1,3,4-oxadiazol-2-ylthio)butanamide (6a–k) compounds were prepared by converting
multifarious phenyl/aryl/aralkyl/heterocyclic organic acids (1a–k) consecutively into the corre-
sponding esters (2a–k), hydrazides (3a–k) and 5-substituted-1,3,4-oxadiazol-2-thiols (4a–k). Finally,
the target compounds 6a–k were synthesized by stirring 5-substituted-1,3,4-oxadiazol-2-thiols
(4a–k) with N-(5-chloro-2-methoxyphenyl)-4-bromobutanamide (5) in the presence of N,N-dimeth-
ylformamide (DMF) and sodium hydride (NaH). The structure elucidation of the synthesized com-
pounds was processed through 1H-NMR, IR and mass spectral data. The synthesized compounds
were screened against lipoxygenase enzyme (LOX) and showed moderately good activities relative
to the reference standard Baicalein.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The heterocyclic compounds have been a concerning domain
of research for sake of invention of biologically effective com-
pounds. The synthesis along with chemical and biological
behavior of oxadiazole derivatives is under consideration of
many researches due to biological, medical and agricultural
effects. Different substituted oxadiazole derivatives show a
Synthesis of new N-(5-chloro-2-methoxyphenyl)-4-(5-substituted-1,3,4-oxadiazol-2-ylthio)butanamide S489variety of pharmacological activities (Dabholkar and Bhusari,
2011). The different substituted 1,3,4-oxadiazole rings expose
antifungal, pesticidal, antibacterial activities, anti-inﬂamma-
tory, antibacterial, antifungal and hypoglycemic activities
(Dabholkar and Bhusari, 2011; Sahin et al., 2002). 1,3,4-oxadi-
azole, a heterocyclic compound, has signiﬁcant interest in
medicinal chemistry due to a wide range of pharmaceutical
and pharmacological applications (Rashid et al., 2012).
Modern researches demonstrated that different alteration
in the structure of compounds having 1,3,4-oxadiazole moiety
would produce compounds with quantitatively as well as qual-
itatively changed biological activities. An attempt is made to
prepare a series of 1,3,4-oxadiazoles having amide functional
group.
Lipoxygenase (LOX, EC 1.13.11.12) goes to a group of
dioxygenases possessing non-haem iron and occurs in both
animals & plants. These have a role in yielding a number of
biologically active lipids taking part in inﬂammation, in ara-
chidonic acid metabolism, in thrombosis & tumor angiogene-
sis, in establishment of fresh capillary vessels from already
present ones, in substantiating many physiological processes
and in exploitation of various pathological conditions. Lipox-
ygenases are potential objectives for medicine design and
mechanism-based inhibitors for ailment of lots of disorders
like inﬂammation, autoimmune diseases etc. (Abbasi et al.,
2005; Alitonou et al., 2006; Byrum et al., 1997; Clapp et al.,
1985; Jensen et al., 1992; Kemal et al., 1987; Steinhilber, 1999).
In continuation of our previous work (Aziz-ur-Rehman
et al., 2012a,b), the synthesis and biological screening of new
N-(5-chloro-2-methoxyphenyl)-4-(5-substituted-1,3,4-oxa-
diazol-2-ylthio)butanamide compounds with an objective to
detect the enzyme inhibition activity of the synthesized com-
pounds. The synthesis was carried out through the intermolec-
ular cyclization of different phenyl/aryl/aralkyl/heterocyclic
organic acid hydrazides to the corresponding 5-substituted-
1,3,4-oxadiazol-2-thiols and ﬁnally to N-(5-chloro-2-methoxy-
phenyl)-4-(5-substituted-1,3,4-oxadiazol-2-ylthio)butanamide
products.
2. Experimental
2.1. General
All the chemical reagents used for synthesis were purchased
from Alfa Aesar and Sigma–Aldrich. All other solvents were
obtained from commercial suppliers and used without further
puriﬁcation. Melting points of the synthesized compounds
were recorded on a Grifﬁn and George melting point appara-
tus using open capillary tube and all were uncorrected. Purity
of the samples was checked by thin layer chromatography
(TLC) using pre-coated silica gel G-25-UV254 plates with ethyl
acetate and n-hexane solvent system giving single spot. Detec-
tion of spots was performed under UV at 254 nm, and by
Ce2SO4 reagent. The I.R. spectra were recorded in KBr (potas-
sium bromide) pellet procedure on a Jasco-320-A spectropho-
tometer and wave number is in cm1. 1H-NMR spectra were
recorded in CDCl3 on a Bruker spectrometers operating at
400 MHz. Chemical shifts are given in ppm with TMS as ref-
erence standard. Mass spectra (EIMS) were recorded on a
JMS-HX-110 spectrometer, with a data system.2.2. General procedure for the synthesis of esters (2a–k)
The phenyl/aryl/aralkyl/heterocyclic organic acids (1a–k;
1.0 g), the absolute ethanol (4.0 mL) and conc. H2SO4 (1/
2 mL) were taken in a 100 mL RB ﬂask ﬁtted with reﬂux con-
denser. The reaction mixture was reﬂuxed for 1.5 h. The reac-
tion completion was established by thin layer chromatography
(TLC). After the completion, reaction mixture was poured into
a separating funnel containing distilled water (40 mL). Diethyl
ether (15 mL) was added to the separating funnel and mixture
was neutralized by conc. aq. sodium carbonate solution till the
pH was ‘9’. The solution was shaken and kept still for some
time. Lower aqueous layer was discarded and upper ether layer
containing required ester was taken in distillation ﬂask.
Diethyl ether was distilled off and the transparent esters (2a–
k) were collected from the ﬂask.
2.3. General procedure for the synthesis of hydrazides (3a–k)
Amixture of esters (2a–k; 0.01 mol) and ethanol (10.0 mL) was
added in the round bottom ﬂask and cooled up to 5 C. 80%
Hydrazine hydrate (2.0 mL) was added slowly in the mixture
and kept on stirring for 0.75 h at the same temperature. Reac-
tion completion was monitored by TLC and cold distilled
water was added on completion. The precipitates were ﬁltered
and washed with distilled water to get the desired hydrazides (
3a–k).
2.4. General procedure for the synthesis of 5-substituted-1,3,4-
oxadiazol-2-thiols (4a–k)
Acid hydrazides (3a–k; 0.01 mol) were dissolved in absolute
ethanol (10.0 mL) in a 100 mL RB ﬂask. Carbon disulﬁde
(0.03 mol) was added to the ﬂask followed by the addition of
potassium hydroxide (0.02 mol). The mixture was reﬂuxed
for 6 h along with proper stirring. The reaction completion
was monitored by TLC. After complete reaction, the mixture
was diluted with distilled water (30 mL) and acidiﬁed with di-
lute HCl to a pH of 2. The precipitated products (4a–k) were
then ﬁltered, washed with distilled water and re-crystallized
from ethanol.
2.5. Procedure for the synthesis of N-(5-chloro-2-
methoxyphenyl)-4-bromobutanamide (5)
5-Chloro-2-methoxyaniline (0.1 mmol) was taken in an iodine
ﬂask (100 mL). The sodium carbonate solution was added to
maintain a pH of 9. Small amount methanol (to dissolve ani-
line) and 4-Bromobutyryl bromide (0.1 mmol) were added to
the mixture. The mixture was shaken vigorously till precipita-
tion. Precipitates were ﬁltered, washed with distilled water,
dried and used for further reaction.
2.6. General procedure for the synthesis of N-(5-chloro-2-
methoxyphenyl)-4-(5-substituted-1,3,4-oxadiazol-2-
ylthio)butanamide (6a–k)
5-Substituted-1,3,4-oxadiazol-2-thiols (4a–k; 0.1 mmol) were
dissolved in N,N-dimethylformamide (DMF) (10.0 mL) in a
S490 Aziz-ur-Rehman et al.50 mL RB ﬂask. After the addition of sodium hydride
(0.1 mmol) to the reaction mixture, stirring for 0.5 h at room
temperature was processed. Then calculated amount of N-(5-
chloro-2-methoxyphenyl)-4-bromobutanamide was added to
the mixture and the solution was further stirred for 3–4 h.
The reaction progress was analyzed through TLC. After com-
pletion of reaction, distilled water was added in the ﬂask and
the product was collected by solvent extraction method
(Aziz-ur-Rehman et al., 2012a,b).2.7. Lipoxygenase assay
Lipoxygenase (LOX) activity was sought almost in accordance
with the already mentioned procedure (Baylac and Racine,
2003; Evans, 1987; Tappel, 1953). 2.0 · 104 L volume of
lipoxygenase assay mixture was prepared containing 1.5 · 10
4 L sodium phosphate buffers (0.1 M and pH of eight) and
1.0 · 105 L compound (required to be tested) and 1.5 · 10
5 L enzyme (6.0 · 102 units well1). The reaction contents
were thoroughly mixed, pre-read at 234 nm and pre-incubated
for 0.16 h at 25 C. The starting of reaction was done by the
addition of 2.5 · 105 L substrate. The variation in absorbance
was ascertained after 0.1 h at 234 nm with the help of 96-well
plate reader Synergy HT, Biotek, USA. All the reactions were
executed in triplicates (threefold) including the positive and
negative controls. Baicalein (0.0005 M well1) was a positive
control. The percentage inhibition (%) was ﬁgured as,
Inhibitionð%Þ ¼ Control Test
Control
 100
where Control is the Total enzyme activity without inhibitor
and Test is the Activity in the presence of test compound.
IC50 values were also estimated by EZ–Fit Enzyme Kinetics
software (Perrella Scientiﬁc Inc. Amherst, USA).2.8. Statistical analysis
All the calculations were accomplished in triplicate (threefold)
and statistical analysis was performed by Microsoft Excel
2010. Results are offered as mean ± sem.2.9. Spectral characterization of the synthesized compounds
2.9.1. N-(5-chloro-2-methoxyphenyl)-4-(5-phenyl-1,3,4-
oxadiazol-2-ylthio)butanamide (6a)
Light pink amorphous solid; Yield: 87%; M. P. 169 C; Molec-
ular formula: C19H18ClN3O3S; Molecular weight: 403 gmol
1;
IR (KBr): mmax (cm
1): 3360 (N–H stretching), 3050 (Ar–H
stretching), 1650 (C‚O stretching), 1530 (Ar C‚C stretch-
ing), 1140 (C–N stretching); 1H-NMR (400 MHz, CDCl3,
ppm): d 8.51 (s, 1H, CON–H), 8.41 (s, 1H, H-600), 7.97 (d,
J= 6.8 Hz, 2H, H-2000, H-6000), 7.45–7.50 (m, 3H, H-3000 to H-
5000), 6.96 (dd, J= 6.4, 2.0 Hz, 1H, H-400), 6.74 (d,
J= 8.4 Hz, 1H, H-300), 3.84 (s, 3H, OCH3-200), 3.40 (t,
J= 6.8 Hz, 2H, H-40), 2.60 (t, J= 6.8 Hz, 2H, H-20), 2.28
(qui, J= 6.8 Hz, 2H, H-30); EIMS: m/z 405 [M+ 2]+, 403
[M]+, 226 [C11H13ClNO2]
+, 198 [C9H9ClNO2]
+, 184[C8H7ClNO2]
+, 156 [C7H7ClNO]
+, 145 [M-C11H13ClNO2S]
+,
141 [C7H6ClO]
+, 119 [M-C12H13ClN2O2S]
+, 103 [M-
C12H13ClN2O3S]
+, 77 [M-C13H13ClN3O3S]
+, 51 [C4H3]
+.
2.9.2. N-(5-chloro-2-methoxyphenyl)-4-(5-(3-nitrophenyl)-
1,3,4-oxadiazol-2-ylthio)butanamide (6b)
Brown amorphous solid; Yield: 83%; M. P. 154 C; Molecular
formula: C19H17ClN4O5S; Molecular weight: 448 gmol
1; IR
(KBr): mmax (cm
1): 3365 (N–H stretching), 3057 (Ar–H
stretching), 1645 (C‚O stretching), 1533 (Ar C‚C stretch-
ing), 1144 (C–N stretching); 1H-NMR (400 MHz, CDCl3,
ppm): d 8.50 (s, 1H, CON–H), 8.40 (s, 1H, H-600), 7.77 (s,
1H, H-2000), 6.98 (dd, J= 6.4, 2.0 Hz, 1H, H-400), 6.90–6.93
(m, 3H, H-4000 to H-6000), 6.75 (d, J= 8.8 Hz, 1H, H-300), 3.85
(s, 3H, OCH3-2
00), 3.35 (t, J= 6.8 Hz, 2H, H-40), 2.56 (t,
J= 6.8 Hz, 2H, H-20), 2.24 (qui, J= 6.8 Hz, 2H, H-30);
EIMS: m/z 450 [M+ 2]+, 448 [M]+, 226 [C11H13ClNO2]
+,
198 [C9H9ClNO2]
+, 190 [M-C11H13ClNO2S]
+, 184
[C8H7ClNO2]
+, 164 [M-C12H13ClN2 O2S]
+, 156
[C7H7ClNO]
+, 148 [M-C12H13ClN2O3S]
+, 141 [C7H6ClO]
+,
122 [M-C13H13ClN3O3S]
+, 51 [C4H3]
+.
2.9.3. N-(5-chloro-2-methoxyphenyl)-4-(5-(4-nitrophenyl)-
1,3,4-oxadiazol-2-ylthio)butanamide (6c)
Pink amorphous solid; Yield: 89%; M. P. 132 C; Molecular
formula: C19H17ClN4O5S; Molecular weight: 448 gmol
1; IR
(KBr): mmax (cm
1): 3364 (N–H stretching), 3056 (Ar–H
stretching), 1648 (C‚O stretching), 1532 (Ar C‚C stretch-
ing), 1143 (C–N stretching); 1H-NMR (400 MHz, CDCl3,
ppm): d 8.40 (s, 1H, CON–H), 8.28 (s, 1H, H-600), 7.94 (d,
J= 8.4 Hz, 2H, H-3000, H-5000), 7.18 (d, J= 8.4 Hz, 2H, H-
2000, H-6000), 6.96 (dd, J= 6.0, 2.4 Hz, 1H, H-400), 6.74 (d,
J= 8.8 Hz, 1H, H-300), 3.84 (s, 3H, OCH3-200), 3.40 (t,
J= 6.8 Hz, 2H, H-40), 2.59 (t, J= 6.8 Hz, 2H, H-20), 2.27
(qui, J= 6.8 Hz, 2H, H-30); EIMS: m/z 450 [M+ 2]+, 448
[M]+, 226 [C11H13ClNO2]
+, 198 [C9H9ClNO2]
+, 190 [M-
C11H13ClNO2S]
+, 184 [C8H7ClNO2]
+, 164 [M-
C12H13ClN2O2S]
+, 156 [C7H7ClNO]
+, 148 [M-C12H13ClN2O3
S]+, 141 [C7H6ClO]
+, 122 [M-C13H13ClN3O3S]
+, 51 [C4H3]
+.2.9.4. N-(5-chloro-2-methoxyphenyl)-4-(5-(2-chlorophenyl)-
1,3,4-oxadiazol-2-ylthio)butanamide (6d)
Light brown amorphous solid; Yield: 85%; M. P. 102 C;
Molecular formula: C19H17Cl2N3O3S; Molecular weight:
437 gmol1; IR (KBr): mmax (cm
1): 3363 (N–H stretching),
3051 (Ar–H stretching), 1649 (C‚O stretching), 1532 (Ar
C‚C stretching), 1146 (C–N stretching); 1H-NMR
(400 MHz, CDCl3, ppm): d 8.50 (s, 1H, CON–H), 8.41 (s,
1H, H-600), 7.91 (dd, J= 6.4, 1.2 Hz, 1H, H-3000), 7.51 (d,
J= 7.6 Hz, 1H, H-6000), 7.43 (ddd, J= 6.8, 1.2 Hz, 1H, H-
4000), 7.37 (ddd, J= 6.8, 1.2 Hz, 1H, H-5000), 6.97 (dd,
J= 6.4, 2.4 Hz, 1H, H-400), 6.74 (d, J= 8.4 Hz, 1H, H-300),
3.85 (s, 3H, OCH3-2
00), 3.41 (t, J= 6.8 Hz, 2H, H-40), 2.60
(t, J= 6.8 Hz, 2H, H-20), 2.29 (qui, J= 6.8 Hz, 2H, H-30);
EIMS: m/z 441 [M+ 4]+, 439 [M+ 2]+, 437 [M]+, 226
[C11H13ClNO2]
+, 198 [C9H9ClNO2]
+, 184 [C8H7ClNO2]
+,
179 [M-C11H13ClNO2S]
+, 156 [C7H7ClNO]
+, 153 [M-
C12H13ClN2O2S]
+, 137 [M-C12H13ClN2O3S]
+, 141
[C7H6ClO]
+, 111 [M-C13H13ClN3O3S]
+, 51 [C4H3]
+.
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1,3,4-oxadiazol-2-ylthio)butanamide (6e)
Grey amorphous solid; Yield: 87%; M. P. 136 C; Molecular
formula: C19H17Cl2N3O3S; Molecular weight: 437 gmol
1; IR
(KBr): mmax (cm
1): 3364 (N–H stretching), 3052 (Ar–H stretch-
ing), 1643 (C‚O stretching), 1533 (Ar C‚C stretching), 1147
(C–N stretching); 1H-NMR (400 MHz, CDCl3, ppm): d 8.52 (s,
1H, CON–H), 8.41 (s, 1H, H-600), 7.91 (d, J= 8.4 Hz, 2H, H-
2000, H-6000), 7.44 (d, J= 8.4 Hz, 2H, H-3000, H-5000), 6.97 (dd,
J= 6.4, 2.0 Hz, 1H, H-400), 6.74 (d, J= 8.4 Hz, 1H, H-300),
3.84 (s, 3H, OCH3-2
00), 3.40 (t, J= 6.8 Hz, 2H, H-40), 2.59 (t,
J= 6.8 Hz, 2H, H-20), 2.28 (qui, J= 6.8 Hz, 2H, H-30); EIMS:
m/z 441 [M+ 4]+, 439 [M+ 2]+, 437 [M]+, 226
[C11H13ClNO2]
+, 198 [C9H9Cl NO2]
+, 184 [C8H7ClNO2]
+,
179 [M-C11H13ClNO2S]
+, 156 [C7H7ClNO]
+, 153 [M-
C12H13ClN2O2S]
+, 137 [M-C12H13 ClN2O3S]
+, 141
[C7H6ClO]
+, 111 [M-C13H13ClN3O3S]
+, 51 [C4H3]
+.
2.9.6. N-(5-chloro-2-methoxyphenyl)-4-(5-(4-aminophenyl)-
1,3,4-oxadiazol-2-ylthio)butanamide (6f)
Grey amorphous solid; Yield: 75%; M. P. 111 C; Molecular
formula: C19H19ClN4O3S; Molecular weight: 418 gmol
1; IR
(KBr): mmax (cm
1): 3358 (N–H stretching), 3049 (Ar–H
stretching), 1640 (C‚O stretching), 1527 (Ar C‚C stretch-
ing), 1137 (C–N stretching); 1H-NMR (400 MHz, CDCl3,
ppm): d 8.41 (s, 1H, CON–H), 8.28 (s, 1H, H-600), 7.94 (d,
J= 8.4 Hz, 2H, H-2000, H-6000), 7.18 (d, J= 8.4 Hz, 2H, H-
3000, H-5000), 6.96 (dd, J= 6.4, 2.8 Hz, 1H, H-400), 6.74 (d,
J= 8.4 Hz, 1H, H-300), 3.85 (s, 2H, N–H), 3.76 (s, 3H,
OCH3-2
00), 3.39 (t, J= 6.8 Hz, 2H, H-40), 2.59 (t,
J= 6.8 Hz, 2H, H-20), 2.28 (qui, J= 6.8 Hz, 2H, H-30);
EIMS: m/z 420 [M+ 2]+, 418 [M]+, 226 [C11H13ClNO2]
+,
198 [C9H9ClNO2]
+, 184 [C8H7ClNO2]
+, 160 [M-
C11H13ClNO2S]
+, 156 [C7H7ClNO]
+, 141 [C7H6ClO]
+, 134
[M-C12H13ClN2O2S]
+, 118 [M-C12H13ClN2O3S]
+, 92 [M-
C13H13ClN3O3S]
+, 51 [C4H3]
+.
2.9.7. N-(5-chloro-2-methoxyphenyl)-4-(5-(4-methylphenyl)-
1,3,4-oxadiazol-2-ylthio)butanamide (6g)
Pink amorphous solid; Yield: 80%; M. P. 107 C; Molecular
formula: C20H20ClN3O3S; Molecular weight: 417 gmol
1; IR
(KBr): mmax (cm
1): 3359 (N–H stretching), 3050 (Ar–H
stretching), 2960 (CH3– stretching), 1647 (C‚O stretching),
1529 (Ar C‚C stretching), 1138 (C–N stretching); 1H-NMR
(400 MHz, CDCl3, ppm): d 8.52 (s, 1H, CON–H), 8.41 (s,
1H, H-600), 7.86 (d, J= 8.0 Hz, 2H, H-2000, H-6000), 7.27 (d,
J= 8.0 Hz, 2H, H-3000, H-5000), 6.96 (dd, J= 6.8, 2.4 Hz, 1H,
H-400), 6.74 (d, J= 8.4 Hz, 1H, H-300), 3.84 (s, 3H, OCH3-
200), 3.40 (t, J= 6.8 Hz, 2H, H-40), 2.60 (t, J= 6.8 Hz, 2H,
H-20), 2.40 (s, 3H, CH3-4000), 2.28 (qui, J= 6.8 Hz, 2H, H-
30); EIMS: m/z 419 [M+ 2]+, 417 [M]+, 226
[C11H13ClNO2]
+, 198 [C9H9ClNO2]
+, 184 [C8H7ClNO2]
+,
159 [M-C11H13ClNO2S]
+, 156 [C7H7ClNO]
+, 141
[C7H6ClO]
+, 133 [M-C12H13ClN2O2S]
+, 117 [M-
C12H13ClN2O3S]
+, 91 [M-C13H13ClN3O3S]
+, 51 [C4H3]
+.
2.9.8. N-(5-chloro-2-methoxyphenyl)-4-(5-(phenylmethyl)-
1,3,4-oxadiazol-2-ylthio)butanamide (6h)
Brown amorphous solid; Yield: 77%; M. P. 150 C; Molecu-
lar formula: C20H20ClN3O3S; Molecular weight: 417 gmol
1;IR (KBr): mmax (cm
1): 3358 (N–H stretching), 3053 (Ar–H
stretching), 2925 (-CH2- stretching), 1653 (C‚O stretching),
1531 (Ar C‚C stretching), 1142 (C–N stretching); 1H-
NMR (400 MHz, CDCl3, ppm): d 8.50 (s, 1H, CON–H),
8.40 (s, 1H, H-600), 7.26–7.32 (m, 5H, H-2000 to H-6000), 6.97
(dd, J= 6.4, 2.4 Hz, 1H, H-400), 6.75 (d, J= 8.8 Hz, 1H,
H-300), 4.14 (s, 2H, H-7000), 3.84 (s, 3H, OCH3-200), 3.30 (t,
J= 6.8 Hz, 2H, H-40), 2.54 (t, J= 6.8 Hz, 2H, H-20), 2.21
(qui, J= 6.8 Hz, 2H, H-30); EIMS: m/z 419 [M+ 2]+, 417
[M]+, 226 [C11H13ClNO2]
+, 198 [C9H9ClNO2]
+, 184
[C8H7ClNO2]
+, 159 [M-C11H13ClNO2S]
+, 156
[C7H7ClNO]
+, 141 [C7H6ClO]
+, 133 [M-C12H13ClN2O2S]
+,
117 [M-C12H13ClN2O3S]
+, 91 [M-C13H13ClN3O3S]
+, 65
[C5H5]
+.
2.9.9. N-(5-chloro-2-methoxyphenyl)-4-(5-(naphthalen-1-
ylmethyl)-1,3,4-oxadiazol-2-ylthio)butanamide (6i)
Yellow amorphous solid; Yield: 79%; M. P. 160 C; Molecular
formula: C24H22ClN3O3S; Molecular weight: 467 gmol
1; IR
(KBr): mmax (cm
1): 3355 (N–H stretching), 3054 (Ar–H
stretching), 2923 (–CH2– stretching), 1651 (C‚O stretching),
1535 (Ar C‚C stretching), 1141 (C–N stretching); 1H-NMR
(400 MHz, CDCl3, ppm): d 8.49 (s, 1H, CON–H), 8.38 (s,
1H, H-600), 8.08 (d, J= 8.4 Hz, 1H, H-4000), 7.85 (d,
J= 7.6 Hz, 1H, H-8000), 7.80 (t, J= 7.2 Hz, 1H, H-7000), 7.76
(brs, 1H, H-5000), 7.51 (ddd, J= 7.2, 1.2 Hz, 1H, H-6000), 7.49
(ddd, J= 6.8, 1.2 Hz, 1H, H-3000), 7.42 (d, J= 6.8 Hz, 1H,
H-2000), 6.97 (dd, J= 6.0, 2.2 Hz, 1H, H-400), 6.74 (d,
J= 8.8 Hz, 1H, H-300), 4.58 (s, 2H, H-11000), 3.82 (s, 3H,
OCH3-2
00), 3.24 (t, J= 6.8 Hz, 2H, H-40), 2.48 (t,
J= 6.8 Hz, 2H, H-20), 2.15 (qui, J= 6.8 Hz, 2H, H-30);
EIMS: m/z 469 [M+ 2]+, 467 [M]+, 226 [C11H13ClNO2]
+,
209 [M-C11H13ClNO2S]
+, 198 [C9H9ClNO2]
+, 184
[C8H7ClNO2]
+, 183 [M-C12H13ClN2O2S]
+, 167 [M-
C12H13ClN2O3S]
+, 156 [C7H7ClNO]
+, 141 [C7H6ClO]
+, 65
[C5H5]
+.2.9.10. N-(5-chloro-2-methoxyphenyl)-4-(5-(1-
(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-
ylthio)butanamide (6j)
Light pink amorphous solid; Yield: 82%; M. P. 147 C; Molec-
ular formula: C24H27ClN4O5S2; Molecular weight: 550 gmol
1; IR (KBr): mmax (cm
1): 3367 (N–H stretching), 3059 (Ar–
H stretching), 1655 (C‚O stretching), 1540 (Ar C‚C stretch-
ing), 1410 (–SO2– stretching), 1149 (C–N stretching);
1H-NMR
(400 MHz, CDCl3, ppm): d 8.51 (s, 1H, CON-H), 8.39 (s, 1H,
H-600), 7.75 (d, J= 7.6 Hz, 2H, H-200 00, H-600 00), 7.59 (t,
J= 7.6 Hz, 2H, H-300 00, H-500 00), 7.52 (t, J= 7.6 Hz, 1H, H-
400 00), 6.97 (dd, J= 6.4, 2.0 Hz, 1H, H-400), 6.75 (d,
J= 8.4 Hz, 1H, H-300), 3.85 (s, 3H, OCH3-200), 3.71 (t,
J= 5.2 Hz, 2H, Heq-2
000, Heq-6000), 3.30 (t, J= 6.8 Hz, 2H, H-
40), 2.82 (t, J= 5.2 Hz, 2H, Hax-2000, Hax-6000), 2.53–2.59 (m,
1H, H-4000), 2.21 (t, J= 6.8 Hz, 2H, H-20), 2.09–2.12 (m, 4H,
H-3000, H-5000), 1.96 (qui, J= 6.8 Hz, 2H, H-30); EIMS:
m/z 552 [M+ 2]+, 550 [M]+, 486 [M-SO2]
+, 292 [M-
C11H13ClNO2S]
+, 266 [M-C12H13ClN2O2S]
+, 250 [M-
C12H13ClN2O3S]
+, 226 [C11H13ClNO2]
+, 224 [M-
C13H13ClN3O3S]
+, 198 [C9H9ClNO2]
+, 184 [C8H7ClNO2]
+,
156 [C7H7ClNO]
+, 141 [C7H6ClO]
+, 83 [C5H9N]
+, 77
[C6H5]
+, 51 [C4H3]
+.
S492 Aziz-ur-Rehman et al.2.9.11. N-(5-chloro-2-methoxyphenyl)-4-(5-styryl-1,3,4-
oxadiazol-2-ylthio)butanamide (6k)
White crystalline solid; Yield: 84%; M. P. 152 C; Molecular
formula: C21H20ClN3O3S; Molecular weight: 429 gmol
1; IR
(KBr): mmax (cm
1): 3368 (N–H stretching), 3057 (Ar–H
stretching), 3030 (–CH‚CH– stretching), 1639 (C‚O stretch-
ing), 1540 (Ar C‚C stretching), 1147 (C–N stretching); 1H-
NMR (400 MHz, CDCl3, ppm): d 8.53 (s, 1H, CON–H),
8.42 (s, 1H, H-600), 7.51 (d, J= 9.2 Hz, 2H, H-2000, H-6000),
7.47 (d, J= 16.4 Hz, 1H, H-8000), 7.37–7.43 (m, 3H, H-3000 to
H-5000), 6.95 (dd, J= 6.4, 3.2 Hz, 1H, H-400), 6.94 (d,
J= 16.4 Hz, 1H, H-7000), 6.75 (d, J= 8.8 Hz, 1H, H-300), 3.85
(s, 3H, OCH3-2
00), 3.39 (t, J= 6.8 Hz, 2H, H-40), 2.59
(t, J= 6.8 Hz, 2H, H-20), 2.28 (qui, J= 6.8 Hz, 2H,
H-30); EIMS: m/z 431 [M+ 2]+, 429 [M]+, 226
[C11H13ClNO2]
+, 198 [C9H9ClNO2]
+, 184 [C8H7ClNO2]
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3. Results and discussion
3.1. Chemistry
The S-substituted 1,3,4-oxadiazole derivatives 6a–k were syn-
thesized according to the protocol sketched in Scheme 1. The
general reaction conditions and the structure characterization
are described in experimental section.
Our objective was to synthesize some new S-substituted
1,3,4-oxadiazole compounds and to ﬁnd out the lipoxygenase
(LOX) enzyme activity of the synthesized compounds. WeC2H5
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Figure 1 Mass fragmentation pattern of N-(5-chloro-2-methoxyphenyl)-4-(5-styryl-1,3,4-oxadiazol-2-ylthio)butanamide (6k).
Table 1 Lipoxygenase enzyme inhibition study of the synthe-
sized compounds.
Sample code LOX
Conc. (mM) Inhibition (%) IC50 (lM)
6a 0.125 65.25 ± 0.52 78.31 ± 0.22
6b 0.125 97.18 ± 0.88 25.91 ± 0.14
6c 0.125 66.44 ± 0.25 75.61 ± 0.16
6d 0.125 74.19 ± 0.64 54.51 ± 0.07
6e 0.125 76.86 ± 0.63 53.21 ± 0.24
6f 0.125 61.28 ± 0.58 83.51 ± 0.14
6g 0.125 47.54 ± 0.42 >100
6h 0.125 54.87 ± 0.33 >100
6i 0.125 71.94 ± 0.61 60.14 ± 0.51
6j 0.125 82.13 ± 0.71 41.21 ± 0.11
6k 0.125 76.17 ± 0.21 52.31 ± 0.33
Control (Baicalein) 0.5 93.79 ± 1.27 22.4 ± 1.3
Note: IC50 values (concentration at which there is 50% enzyme
inhibition) of compounds were calculated using EZ–Fit Enzyme
kinetics software (Perella Scientiﬁc Inc. Amherst, USA).
LOX= Lipoxygenase enzyme.
Synthesis of new N-(5-chloro-2-methoxyphenyl)-4-(5-substituted-1,3,4-oxadiazol-2-ylthio)butanamide S493synthesized different N-(5-chloro-2-methoxyphenyl)-4-(5-
substituted-1,3,4-oxadiazol-2-ylthio)butanamides in excellent
yields having good biological activities. The synthesis was per-
formed in different steps. Foremost step includes the
formation of ethyl esters (2a–k) from corresponding carboxylic
acids (1a–k) in the presence of conc. H2SO4 and ethanol by
reﬂuxing for 5–6 h. Secondly, the ethyl esters were converted
into corresponding carbohydrazides (3a–k) by stirring for
4–5 h with hydrated hydrazine (80%) in an alcoholic medium.
Further, the compounds 3a–k were synthesized by the
intermolecular cyclization to the analogous 5-substituted-
1,3,4-oxadiazol-2-thiols and ﬁnally a series of N-(5-chloro-2-
methoxyphenyl)-4-(5-substituted-1,3,4-oxadiazol-2-
ylthio)butanamides (6a–k) were obtained after the reaction of
N-(5-chloro-2-methoxyphenyl)-4-bromobutanamide (5) with
5-substituted-1,3,4-oxadiazol-2-thiols 4a–k in the presence of
DMF (N,N-dimethylformamide) and sodium hydride (NaH)
which acts as a base (Scheme 1). The structures of the synthe-
sized compounds were ascertained by 1H-NMR, IR and mass
spectral data as illustrated in experimental section.
Compound 6a was synthesized as light pink amorphous so-
lid having a yield of 87% and melting point of 169 C. The
molecular formula C19H18ClN3O3S was set up viaEI-MS show-
ing molecular ion peak at m/z 403 and by counting the number
of protons in 1H-NMR spectrum. In the IR spectrum, the
absorption bands appeared at 3360 cm1, 3050 cm1,
1650 cm1, 1530 cm1 and 1140 cm1 due to stretching ofN–H (amide), C–H (aromatic ring), C‚O (amidic carbonyl
group), C‚C (aromatic ring), C–N (amide group) respectively.
Two stretching bands at 1600–1620 cm1 for (C‚N–N‚C)
S494 Aziz-ur-Rehman et al.and at 1063–1073 cm1 for (C–O–C) in compounds conﬁrmed
the presence of 1,3,4-oxadiazole ring. The EI-MS also gave
two distinct peaks at m/z 226 because of N-(5-chloro-2-
methoxyphenyl)-4-ylbutanamide cation and at m/z 145 due to
5-phenyl-1,3,4-oxadiazol-2-yl cation. The 1H-NMR spectrum
showed three signals at d 8.41 (s, 1H, H-600), 6.96 (dd, J= 6.4,
2.0 Hz, 1H, H-400) and 6.74 (d, J= 8.4 Hz, 1H, H-300) in aro-
matic region; and one signal at 3.84 (s, 3H, OCH3-2
00 in aliphatic
region owing to protons of 5-chloro-2-methoxyaniline ring.
Two signals at d 7.97 (d, J= 6.8 Hz, 2H, H-2000, H-6000) and
7.45–7.50 (m, 3H,H-3000 to H-5000) conﬁrmed the presence of phe-
nyl group attached to oxadiazole ring. The four signals emerg-
ing at d 8.51 (s, 1H, CON–H), 3.40 (t, J= 6.8 Hz, 2H, H-40),
2.60 (t, J= 6.8 Hz, 2H, H-20) and 2.28 (qui, J= 6.8 Hz, 2H,
H-30) depicted the presence of butanamide group in the mole-
cule. On the ground of all the above accumulative data, the
structure of 6a was conﬁrmed as N-(5-chloro-2-methoxy-
phenyl)-4-(5-phenyl-1,3,4-oxadiazol-2-ylthio)butanamide. The
mass fragmentation pattern of N-(5-chloro-2-methoxy-
phenyl)-4-(5-styryl-1,3,4-oxadiazol-2-ylthio)butanamide (6k)
was clearly outlined in Fig. 1. Likewise, the structures of other
synthesized products were corroborated on the basis of spectral
evidences from IR, EI-MS and 1H-NMR as described in exper-
imental section.
3.2. Enzyme inhibition activity (in vitro)
The results of in vitro enzyme inhibition activity of the synthe-
sized compounds against lipoxygenase are described in Table 1.
The screening of the synthesized N-(5-chloro-2-methoxy-
phenyl)-4-(5-substituted-1,3,4-oxadiazol-2-ylthio)butanamide
derivatives against lipoxygenase enzymes exposed that almost
all of them exhibited promising inhibitory potential against
lipoxygenase (LOX) enzyme except N-(5-chloro-2-methoxy-
phenyl)-4-(5-(4-methylphenyl)-1,3,4-oxadiazol-2-ylthio)butana-
mide (6g) and N-(5-chloro-2-methoxyphenyl)-4-(5-
(phenylmethyl)-1,3,4-oxadiazol-2-ylthio)butanamide (6h). The
compound N-(5-chloro-2-methoxyphenyl)-4-(5-(3-nitro-
phenyl)-1,3,4-oxadiazol-2-ylthio) butanamide (6b) displayed a
very good inhibiting activity as its IC50 value
(25.91 ± 0.14 lmol/L) was very close to the reference
standard, Baicalein, having IC50 value of 22.4 ± 1.3 lmol/L,
probably due to the presence of meta-substituted nitrobenzene
ring in the molecule. Another compound N-(5-chloro-2-
methoxyphenyl)-4-(5-(1-(phenylsulfonyl)piperidin-4-yl)-1,3,4-
oxadiazol-2-ylthio)butanamide (6j) also displayed the good
inhibiting activity with IC50 value of 41.21 ± 0.11 lmol/L rel-
ative to the reference, possibly due to the attachment of sul-
fonylpiperidine group in this molecule. Such type of
compounds can further be exploited and their derivatives
could be synthesized to get closer to IC50 values of the stan-
dard, Baicalein. In this way, the compounds could be potential
target in the drug invention and drug development program.
4. Conclusion
The demoed compounds were synthesized with an aim to
introduce the potent inhibitors of lipoxygenase enzyme(LOX). The most of synthesized compounds were found to
be active against the enzyme as supported by their IC50 values.
Also our aim to combine amide functionality and oxadiazole
moiety, remained fruitful with potent inhibitory effect. In
short, we have inaugurated a series of compounds with hand-
some biological activity and the synthesized compounds can be
assistive for the pharmaceutical industries in designing of
medicines.
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